Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference

NEW YORK, NY – April 23, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 at 11:10 a.m. ET at The Washington Hilton in Washington, DC. In a…

Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries

Report Further Validates Therapeutic Application of Proprietary Anavex Compounds in Multiple Neurological Diseases NEW YORK, NY – April 7, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) is encouraged by the findings of a new report in the latest issue of peer-reviewed scientific journal Neuroscience Letters. The study demonstrates for the first time…